Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies
WTK Tsai, Y Li, Z Yin, P Tran, Q Phung, Z Zhou, K Peng… - Mabs, 2024 - Taylor & Francis
Bispecific antibodies, including bispecific IgG, are emerging as an important new class of
antibody therapeutics. As a result, we, as well as others, have developed engineering …
antibody therapeutics. As a result, we, as well as others, have developed engineering …
Immunogenicity Risk Assessment of Process-Related Impurities in An Engineered T Cell Receptor Cellular Product
J Mora, D Forman, J Hu, A Ijantkar, J Gokemeijer… - Journal of …, 2024 - Elsevier
Cell therapies such as genetically modified T cells have emerged as a promising and viable
treatment for hematologic cancers and are being aggressively pursued for a wide range of …
treatment for hematologic cancers and are being aggressively pursued for a wide range of …